Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (976)	11/21/1997 8:39:00 PM
From: David Bogdanoff	Respond to of 2173

DR: Regarding the sample size of studies. Its not possible for me to ascertain the proper sample size for AMLS's studies from the information made available to the public. Usually the sample size is choses so that the study has at least 80% chance of detecting a significant difference, assumming some minimum level of efficacy. As you can see, certainty is not guaranteed even when the study drug is efficacious; luck can be against you. This is true for any drug study, not just AMLN's. I am inclined to think AMLS's chances of success to be rather good base on the large committment from J&J. David